SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Edward Boghosian who wrote (1686)1/10/2000 8:52:00 PM
From: arnie h  Respond to of 2173
 
Ed: When you put this together with the Pramlinitide effort, it is beginning to appear these folks may become a real factor in the diabetes area. They appear to be having success addressing not only glucose control but other key facets that impact the disease; weight and lipid control. They sure seem to be heading in the right direction.

Arnie



To: Edward Boghosian who wrote (1686)1/25/2000 7:32:00 PM
From: Edward Boghosian  Read Replies (1) | Respond to of 2173
 
> <https://www.siliconinvestor.com/subject.aspx?subjectid=6136>.
> ..
Just fooling around


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News